

Mark Pimentel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2691286/publications.pdf>

Version: 2024-02-01

261
papers

11,458
citations

30070
54
h-index

30922
102
g-index

271
all docs

271
docs citations

271
times ranked

6194
citing authors

#	ARTICLE	IF	CITATIONS
1	Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation. New England Journal of Medicine, 2011, 364, 22-32.	27.0	880
2	Eradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of Irritable Bowel Syndrome. American Journal of Gastroenterology, 2000, 95, 3503-3506.	0.4	649
3	Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology, 2003, 98, 412-419.	0.4	586
4	Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. American Journal of Gastroenterology, 2017, 112, 775-784.	0.4	525
5	The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome. Annals of Internal Medicine, 2006, 145, 557.	3.9	417
6	Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. American Journal of Physiology - Renal Physiology, 2006, 290, G1089-G1095.	3.4	361
7	ACG Clinical Guideline: Management of Irritable Bowel Syndrome. American Journal of Gastroenterology, 2021, 116, 17-44.	0.4	341
8	A Systematic Review of Diagnostic Tests for Small Intestinal Bacterial Overgrowth. Digestive Diseases and Sciences, 2008, 53, 1443-1454.	2.3	248
9	ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. American Journal of Gastroenterology, 2020, 115, 165-178.	0.4	224
10	Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Digestive Diseases and Sciences, 2003, 48, 86-92.	2.3	216
11	Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology, 2016, 151, 1113-1121.	1.3	209
12	Methane and the Gastrointestinal Tract. Digestive Diseases and Sciences, 2010, 55, 2135-2143.	2.3	185
13	Methanogens, Methane and Gastrointestinal Motility. Journal of Neurogastroenterology and Motility, 2014, 20, 31-40.	2.4	183
14	The Degree of Breath Methane Production in IBS Correlates With the Severity of Constipation. American Journal of Gastroenterology, 2007, 102, 837-841.	0.4	181
15	The Prevalence of Overgrowth by Aerobic Bacteria in the Small Intestine by Small Bowel Culture: Relationship with Irritable Bowel Syndrome. Digestive Diseases and Sciences, 2012, 57, 1321-1329.	2.3	159
16	Measurement of Gastrointestinal Transit. Digestive Diseases and Sciences, 2005, 50, 989-1004.	2.3	153
17	Methane on Breath Testing Is Associated with Constipation: A Systematic Review and Meta-analysis. Digestive Diseases and Sciences, 2011, 56, 1612-1618.	2.3	151
18	Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. Therapeutic Advances in Chronic Disease, 2013, 4, 223-231.	2.5	141

#	ARTICLE	IF	CITATIONS
19	Abnormal Breath Testing in IBS: A Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2441-2449.	2.3	140
20	Neomycin Improves Constipation-Predominant Irritable Bowel Syndrome in a Fashion That Is Dependent on the Presence of Methane Gas: Subanalysis of a Double-Blind Randomized Controlled Study. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1297-1301.	2.3	137
21	Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. <i>Digestive Diseases and Sciences</i> , 2002, 47, 2639-2643.	2.3	136
22	Methanobrevibacter smithii Is the Predominant Methanogen in Patients with Constipation-Predominant IBS and Methane on Breath. <i>Digestive Diseases and Sciences</i> , 2012, 57, 3213-3218.	2.3	127
23	Identification of A Prodromal Period in Crohn's Disease But Not Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2000, 95, 3458-3462.	0.4	124
24	A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 450-452.	0.9	124
25	Rifaximin versus Other Antibiotics in the Primary Treatment and Retreatment of Bacterial Overgrowth in IBS. <i>Digestive Diseases and Sciences</i> , 2008, 53, 169-174.	2.3	117
26	Development and Validation of a Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects. <i>PLoS ONE</i> , 2015, 10, e0126438.	2.5	114
27	How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach. <i>Current Gastroenterology Reports</i> , 2016, 18, 8.	2.5	113
28	Microbiome and Its Role in Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2020, 65, 829-839.	2.3	111
29	Antibiotic Treatment of Constipation-Predominant Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1278-1285.	2.3	103
30	Studying the Overlap Between IBS and GERD: A Systematic Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2006, 51, 2113-2120.	2.3	88
31	Effects of Rifaximin Treatment and Retreatment in Nonconstipated IBS Subjects. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2067-2072.	2.3	86
32	Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 1076-1087.	1.5	85
33	Review of rifaximin as treatment for SIBO and IBS. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 349-358.	4.1	84
34	AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. <i>Gastroenterology</i> , 2020, 159, 1526-1532.	1.3	84
35	Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome “An Update. <i>Frontiers in Psychiatry</i> , 2020, 11, 664.	2.6	82
36	A Combination of Rifaximin and Neomycin Is Most Effective in Treating Irritable Bowel Syndrome Patients With Methane on Lactulose Breath Test. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 547-550.	2.2	79

#	ARTICLE	IF	CITATIONS
37	A New Rat Model Links Two Contemporary Theories in Irritable Bowel Syndrome. Digestive Diseases and Sciences, 2008, 53, 982-989.	2.3	76
38	Peppermint Oil Improves the Manometric Findings in Diffuse Esophageal Spasm. Journal of Clinical Gastroenterology, 2001, 33, 27-31.	2.2	75
39	Evaluating Breath Methane as a Diagnostic Test for Constipation-Predominant IBS. Digestive Diseases and Sciences, 2010, 55, 398-403.	2.3	74
40	Gas and the Microbiome. Current Gastroenterology Reports, 2013, 15, 356.	2.5	74
41	A 14-Day Elemental Diet Is Highly Effective in Normalizing the Lactulose Breath Test. Digestive Diseases and Sciences, 2004, 49, 73-77.	2.3	73
42	Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following Campylobacter jejuni Infection in a Rat Model. Digestive Diseases and Sciences, 2015, 60, 1195-1205.	2.3	70
43	THE PRESENCE OF CONSTIPATION AND METHANE ON LACTULOSE BREATH TEST IN IBS SUBJECTS IS ASSOCIATED WITH LOWER SEROTONIN LEVELS COMPARED TO HYDROGEN ALONE. American Journal of Gastroenterology, 2003, 98, S72.	0.4	69
44	Evaluation of Harm in the Pharmacotherapy of Irritable Bowel Syndrome. American Journal of Medicine, 2012, 125, 381-393.	1.5	68
45	The duodenal microbiome is altered in small intestinal bacterial overgrowth. PLoS ONE, 2020, 15, e0234906.	2.5	68
46	Age and the aging process significantly alter the small bowel microbiome. Cell Reports, 2021, 36, 109765.	6.4	67
47	Evidence- and Consensus-Based Practice Guidelines for the Diagnosis of Irritable Bowel Syndrome. Archives of Internal Medicine, 2001, 161, 2081.	3.8	65
48	Mapping the Segmental Microbiomes in the Human Small Bowel in Comparison with Stool: A REIMAGINE Study. Digestive Diseases and Sciences, 2020, 65, 2595-2604.	2.3	65
49	Increased Prevalence of Irritable Bowel Syndrome in Patients With Gastroesophageal Reflux. Journal of Clinical Gastroenterology, 2002, 34, 221-224.	2.2	64
50	Breath Testing To Evaluate Lactose Intolerance in Irritable Bowel Syndrome Correlates With Lactulose Testing and May Not Reflect True Lactose Malabsorption. American Journal of Gastroenterology, 2003, 98, 2700-2704.	0.4	64
51	Methanogens in Human Health and Disease. American Journal of Gastroenterology Supplements (Print), 2012, 1, 28-33.	0.7	64
52	Aberrant TGF- β 2 Production and Regulation in Metastatic Malignancy. Growth Factors, 1990, 3, 115-127.	1.7	62
53	Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Alimentary Pharmacology and Therapeutics, 2016, 43, 37-49.	3.7	61
54	Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome. BMC Gastroenterology, 2012, 12, 55.	2.0	59

#	ARTICLE	IF	CITATIONS
55	Lactose Intolerance and the Role of the Lactose Breath Test. American Journal of Gastroenterology, 2010, 105, 1726-1728.	0.4	58
56	Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness. BMC Gastroenterology, 2013, 13, 46.	2.0	57
57	Measuring response in the gastrointestinal tract in systemic sclerosis. Current Opinion in Rheumatology, 2013, 25, 700-706.	4.3	57
58	Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. Gut Microbes, 2019, 10, 22-33.	9.8	57
59	T1390 Rifaximin for the Treatment of Diarrhea-Associated Irritable Bowel Syndrome: Short Term Treatment Leading to Long Term Sustained Response. Gastroenterology, 2008, 134, A-545.	1.3	56
60	Bacteria and irritable bowel syndrome: The evidence for small intestinal bacterial overgrowth. Current Gastroenterology Reports, 2006, 8, 305-311.	2.5	53
61	Role of Cytolethal Distending Toxin in Altered Stool Form and Bowel Phenotypes in a Rat Model of Post-infectious Irritable Bowel Syndrome. Journal of Neurogastroenterology and Motility, 2012, 18, 434-442.	2.4	53
62	Intestinal <i>Methanobrevibacter smithii</i> but not total bacteria is related to diet-induced weight gain in rats. Obesity, 2013, 21, 748-754.	3.0	53
63	IBS Subjects with Methane on Lactulose Breath Test Have Lower Postprandial Serotonin Levels Than Subjects with Hydrogen. Digestive Diseases and Sciences, 2004, 49, 84-87.	2.3	51
64	Pathogen-Specific Risk of Celiac Disease Following Bacterial Causes of Foodborne Illness: A Retrospective Cohort Study. Digestive Diseases and Sciences, 2013, 58, 3242-3245.	2.3	50
65	Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea. American Journal of Gastroenterology, 2019, 114, 1886-1893.	0.4	45
66	Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. Digestive Diseases and Sciences, 2017, 62, 2455-2463.	2.3	43
67	Biomarkers of Irritable Bowel Syndrome. Journal of Neurogastroenterology and Motility, 2017, 23, 20-26.	2.4	43
68	Esophageal Motor Dysfunction and Gastroesophageal Reflux Are Prevalent in Lung Transplant Candidates. Annals of Thoracic Surgery, 2010, 90, 1630-1636.	1.3	42
69	Placebo Effect in Clinical Trial Design for Irritable Bowel Syndrome. Journal of Neurogastroenterology and Motility, 2014, 20, 163-170.	2.4	42
70	In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. International Journal of Antimicrobial Agents, 2014, 43, 236-241.	2.5	41
71	Ultraviolet A light effectively reduces bacteria and viruses including coronavirus. PLoS ONE, 2020, 15, e0236199.	2.5	40
72	Estimating the Contribution of Acute Gastroenteritis to the Overall Prevalence of Irritable Bowel Syndrome. Journal of Neurogastroenterology and Motility, 2012, 18, 200-204.	2.4	38

#	ARTICLE	IF	CITATIONS
73	ICC density predicts bacterial overgrowth in a rat model of post-infectious IBS. World Journal of Gastroenterology, 2010, 16, 3680.	3.3	38
74	Antibiotics for Irritable Bowel Syndrome: Rationale and Current Evidence. Current Gastroenterology Reports, 2012, 14, 439-445.	2.5	37
75	Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage. BMC Gastroenterology, 2016, 16, 67.	2.0	37
76	Viscerotaxis of the bowel in the hypermobility type of Ehlers-Danlos syndrome: Presentation of a rare manifestation and review of the literature. European Journal of Medical Genetics, 2012, 55, 548-551.	1.3	36
77	Gut Microbiota Dysbiosis in Functional Dyspepsia. Microorganisms, 2020, 8, 691.	3.6	36
78	Irritable Bowel Syndrome and Small Intestinal Bacterial Overgrowth. Journal of Clinical Gastroenterology, 2010, 44, 672-675.	2.2	35
79	The Effect of Rifaximin on Gut Flora and Staphylococcus Resistance. Digestive Diseases and Sciences, 2013, 58, 1676-1682.	2.3	35
80	Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome. Digestive Diseases and Sciences, 2017, 62, 1480-1485.	2.3	35
81	Polycystic Ovary Syndrome Is Associated with an Increased Prevalence of Irritable Bowel Syndrome. Digestive Diseases and Sciences, 2010, 55, 1085-1089.	2.3	34
82	Fecal Incontinence in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflammatory Bowel Diseases, 2018, 24, 1280-1290.	1.9	34
83	Intestinal methane production in obese individuals is associated with a higher body mass index. Gastroenterology and Hepatology, 2012, 8, 22-8.	0.1	33
84	Quantitative sequencing clarifies the role of disruptor taxa, oral microbiota, and strict anaerobes in the human small-intestine microbiome. Microbiome, 2021, 9, 214.	11.1	31
85	New Clinical Method for Distinguishing D-IBS from Other Gastrointestinal Conditions Causing Diarrhea: The LA/IBS Diagnostic Strategy. Digestive Diseases and Sciences, 2010, 55, 145-149.	2.3	30
86	Proton Pump Inhibitor Therapy Does Not Affect Hydrogen Production on Lactulose Breath Test in Subjects with IBS. Digestive Diseases and Sciences, 2010, 55, 2302-2308.	2.3	30
87	Apple Sauce Improves Detection of Esophageal Motor Dysfunction During High-Resolution Manometry Evaluation of Dysphagia. Digestive Diseases and Sciences, 2011, 56, 1723-1728.	2.3	30
88	Irritable bowel syndrome: Bacterial overgrowth—What's known and what to do. Current Treatment Options in Gastroenterology, 2007, 10, 328-337.	0.8	29
89	Gender distribution in irritable bowel syndrome is proportional to the severity of constipation relative to diarrhea. Gender Medicine, 2010, 7, 240-246.	1.4	29
90	Evaluating a Bacterial Hypothesis in IBS Using a Modification of Koch's Postulates: Part 1. American Journal of Gastroenterology, 2010, 105, 718-721.	0.4	29

#	ARTICLE	IF	CITATIONS
91	Acute and Chronic Histological Changes of the Small Bowel Secondary to <i>C. jejuni</i> Infection in a Rat Model for Post-Infectious IBS. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2575-2584.	2.3	29
92	Optimizing microbiome sequencing for small intestinal aspirates: validation of novel techniques through the REIMAGINE study. <i>BMC Microbiology</i> , 2019, 19, 239.	3.3	28
93	Inflammation and Microflora. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 69-85.	2.2	27
94	Effect of repeated <i>Campylobacter jejuni</i> infection on gut flora and mucosal defense in a rat model of post infectious functional and microbial bowel changes. <i>Neurogastroenterology and Motility</i> , 2013, 25, 529.	3.0	26
95	Metabolic effects of eradicating breath methane using antibiotics in prediabetic subjects with obesity. <i>Obesity</i> , 2016, 24, 576-582.	3.0	26
96	Breath Testing for Small Intestinal Bacterial Overgrowth: Should We Bother?. <i>American Journal of Gastroenterology</i> , 2016, 111, 307-308.	0.4	24
97	Second-Generation Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3115-3121.	2.3	24
98	Is small intestinal bacterial overgrowth involved in the pathogenesis of functional dyspepsia?. <i>Medical Hypotheses</i> , 2017, 106, 26-32.	1.5	23
99	Dyssynergic Defecation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1065-1073.	1.9	23
100	Effects of Proton Pump Inhibitors on the Small Bowel and Stool Microbiomes. <i>Digestive Diseases and Sciences</i> , 2022, 67, 224-232.	2.3	23
101	Antibiotics for the treatment of irritable bowel syndrome. <i>Gastroenterology and Hepatology</i> , 2011, 7, 455-93.	0.1	23
102	An Approach to the Patient With Chronic Undiagnosed Abdominal Pain. <i>American Journal of Gastroenterology</i> , 2019, 114, 726-732.	0.4	21
103	Severity of Dyspeptic Symptoms Correlates with Delayed and Early Variables of Gastric Emptying. <i>Digestive Diseases and Sciences</i> , 2012, 58, 478-87.	2.3	20
104	Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway. <i>F1000Research</i> , 2016, 5, 606.	1.6	20
105	Adverse events appear to unblind clinical trials in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2014, 26, 482-488.	3.0	19
106	Small Intestinal Bacterial Overgrowth: A Possible Association with Fibromyalgia. <i>Journal of Musculoskeletal Pain</i> , 2001, 9, 105-113.	0.3	18
107	Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 689-699.	3.2	18
108	Postprandial improvement of gastric dysrhythmias in patients with type II diabetes: identification of responders and nonresponders. <i>Digestive Diseases and Sciences</i> , 2001, 46, 705-712.	2.3	17

#	ARTICLE	IF	CITATIONS
109	Mo1641 Efficacy and Tolerability of Linaclotide and Plecanatide in Treating Irritable Bowel Syndrome With Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC): A Meta-Analysis. <i>Gastroenterology</i> , 2016, 150, S739.	1.3	16
110	Acute appendicitis is associated with appendiceal microbiome changes including elevated <i>Campylobacter jejuni</i> levels. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000412.	2.7	16
111	Evidence-based management of irritable bowel syndrome with diarrhea. <i>American Journal of Managed Care</i> , 2018, 24, S35-S46.	1.1	16
112	An Evidence-Based Treatment Algorithm for IBS Based on a Bacterial/SIBO Hypothesis: Part 2. <i>American Journal of Gastroenterology</i> , 2010, 105, 1227-1230.	0.4	15
113	Antibiotic Prophylaxis Prevents the Development of a Post-Infectious Phenotype in a New Rat Model of Post-Infectious IBS. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1962-1966.	2.3	15
114	Influence of Dietary Restriction on Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2019, 114, 212-220.	0.4	15
115	Rifaximin, a Non-Absorbable Antibiotic, Improves the Symptoms of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2005, 100, S324.	0.4	15
116	Pre-cebo. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 686-690.	2.2	14
117	Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	14
118	High Prevalence of Small Intestinal Bacterial Overgrowth among Functional Dyspepsia Patients. <i>Digestive Diseases</i> , 2021, 39, 382-390.	1.9	14
119	A Single Fasting Exhaled Methane Level Correlates With Fecal Methanogen Load, Clinical Symptoms and Accurately Detects Intestinal Methanogen Overgrowth. <i>American Journal of Gastroenterology</i> , 2022, 117, 470-477.	0.4	14
120	A High-resolution View of Achalasia. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 644-651.	2.2	13
121	Relationships Among the Lactulose Breath Test, Intestinal Gas Volume, and Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2059-2066.	2.3	13
122	Factor Analysis Demonstrates a Symptom Cluster Related to Methane and Non-methane Production in Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 40-44.	2.2	12
123	Evaluating the functional net value of pharmacologic agents in treating irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 973-983.	3.7	12
124	Intestinal methane production is associated with decreased weight loss following bariatric surgery. <i>Obesity Research and Clinical Practice</i> , 2016, 10, 728-733.	1.8	12
125	Breath Test Gas Patterns in Inflammatory Bowel Disease with Concomitant Irritable Bowel Syndrome-Like Symptoms: A Controlled Large-Scale Database Linkage Analysis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2388-2396.	2.3	12
126	Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00144.	2.5	12

#	ARTICLE	IF	CITATIONS
127	Accurate Identification of Excessive Methane Gas Producers by a Single Fasting Measurement of Exhaled Methane: A Large-scale Database Analysis ACG Category Award. American Journal of Gastroenterology, 2015, 110, S759-S760.	0.4	12
128	Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Gastroenterology and Hepatology, 2009, 5, 435-42.	0.1	12
129	Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology, 2003, 98, 412-419.	0.4	11
130	History of Tonsillectomy Is Associated With Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2011, 45, 912.	2.2	11
131	Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SSc cohorts. Clinical Rheumatology, 2021, 40, 2277-2284.	2.2	11
132	Immunization with cytolethal distending toxin B produces autoantibodies to vinculin and small bowel bacterial changes in a rat model of postinfectious irritable bowel syndrome. Neurogastroenterology and Motility, 2020, 32, e13875.	3.0	11
133	Smoking has disruptive effects on the small bowel luminal microbiome. Scientific Reports, 2022, 12, 6231.	3.3	11
134	Healthy control subjects are poorly defined in case-control studies of irritable bowel syndrome. Annals of Gastroenterology, 2015, 28, 87-93.	0.6	10
135	Irritable Bowel Syndrome in Pregnancy. American Journal of Gastroenterology, 2021, 116, 480-490.	0.4	9
136	Evaluation of peripapillary lymphocytosis and lymphocytic esophagitis in adult inflammatory bowel disease. Gastroenterology and Hepatology, 2013, 9, 505-11.	0.1	9
137	Duodenal microbiome changes in postmenopausal women: effects of hormone therapy and implications for cardiovascular risk. Menopause, 2022, 29, 264-275.	2.0	9
138	Serum sTREM-1 as a Surrogate Marker of Treatment Outcome in Patients with Peptic Ulcer Disease. Digestive Diseases and Sciences, 2011, 56, 3590-3595.	2.3	8
139	Tu2110 Circulating Antibodies to Cytolethal Distending Toxin B Correlate With the Development of Small Intestinal Bacterial Overgrowth in a Rat Model of Post-Infectious IBS. Gastroenterology, 2013, 144, S-931-S-932.	1.3	8
140	Lovastatin Lactone Inhibits Methane Production in Human Stool Homogenates. American Journal of Gastroenterology, 2015, 110, S753.	0.4	8
141	Su1210 SYN-010, a Proprietary Modified-Release Formulation of Lovastatin Lactone, Lowered Breath Methane and Improved Stool Frequency in Patients With IBS-C: Results of a Multi-Center Randomized Double-Blind Placebo-Controlled Phase 2a Trial. Gastroenterology, 2016, 150, S496-S497.	1.3	8
142	A Predictive Model to Estimate Cost Savings of a Novel Diagnostic Blood Panel for Diagnosis of Diarrhea-predominant Irritable Bowel Syndrome. Clinical Therapeutics, 2016, 38, 1638-1652.e9.	2.5	8
143	Comparing the rates of methane production in patients with and without appendectomy: results from a large-scale cohort. Scientific Reports, 2020, 10, 867.	3.3	8
144	Endotracheal Application of Ultraviolet-A Light in Critically Ill Patients with Severe Acute Respiratory Syndrome Coronavirus-2: A First-in-Human Study. Advances in Therapy, 2021, 38, 4556-4568.	2.9	8

#	ARTICLE	IF	CITATIONS
145	475i Rifaximin Treatment for 2 Weeks Provides Acute and Sustained Relief Over 12 Weeks of IBS Symptoms in Non-Constipated Irritable Bowel Syndrome: Results From 2 North American Phase 3 Trials (Target 1 and Target 2). <i>Gastroenterology</i> , 2010, 138, S-64-S-65.	1.3	7
146	A Smartphone Application Using Artificial Intelligence Is Superior To Subject Self-Reporting When Assessing Stool Form. <i>American Journal of Gastroenterology</i> , 2022, 117, 1118-1124.	0.4	7
147	Small Bowel Culture Confirms the Presence of Small Intestinal Bacterial Overgrowth in a Subset of IBS Subjects. <i>Gastroenterology</i> , 2011, 140, S-152.	1.3	6
148	Breath Testing for Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Metaanalysis. <i>American Journal of Gastroenterology</i> , 2015, 110, S762-S763.	0.4	6
149	Bacterial concepts in irritable bowel syndrome. <i>Reviews in Gastroenterological Disorders</i> , 2005, 5 Suppl 3, S3-9.	0.6	6
150	Do antibiotics influence IBS?. <i>American Journal of Gastroenterology</i> , 2002, 97, 2681-2681.	0.4	5
151	Gastroesophageal Reflux Reported on Esophagram Does Not Correlate with pH Monitoring and High-resolution Esophageal Manometry. <i>American Surgeon</i> , 2014, 80, 1026-1029.	0.8	5
152	Understanding Breath Tests for Small Intestinal Bacterial Overgrowth. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1362-1363.	4.4	5
153	Campylobacter infection and the link with Irritable Bowel Syndrome: on the pathway towards a causal association. <i>Pathogens and Disease</i> , 2022, 80, .	2.0	5
154	Small Intestine Bacterial Overgrowth Can Form an Indigenous Proinflammatory Environment in the Duodenum: A Prospective Study. <i>Microorganisms</i> , 2022, 10, 960.	3.6	5
155	Probiotics for Antibiotic-Associated Diarrhea: PLACIDE Swings the Pendulum. <i>Gastroenterology</i> , 2014, 146, 1822-1823.	1.3	4
156	Mo1865 Prevalence of Excessive Intestinal Methane Production and Its Variability With Age and Gender: A Large-Scale Database Analysis. <i>Gastroenterology</i> , 2015, 148, S-729-S-730.	1.3	4
157	450 Hydrogen- and Methane- Based Breath Testing (BT) in Gastrointestinal (GI) Disorders: Report of the North American Consensus Meeting. <i>Gastroenterology</i> , 2016, 150, S97.	1.3	4
158	Measurement of Hydrogen Sulfide during Breath Testing Correlates to Patient Symptoms. <i>Gastroenterology</i> , 2017, 152, S205-S206.	1.3	4
159	Response to Dr. Parisi et al.. <i>American Journal of Gastroenterology</i> , 2003, 98, 2573-2574.	0.4	3
160	Concomitant Methane and Hydrogen Production in Humans is Associated With a Higher Body Mass Index. <i>Gastroenterology</i> , 2011, 140, S-335.	1.3	3
161	Importance of Diarrhea in Evaluating Constipation in Irritable Bowel Syndrome Clinical Studies. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 790-793.	2.2	3
162	A definitive blood test for post-infectious irritable bowel syndrome?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1197-1199.	3.0	3

#	ARTICLE	IF	CITATIONS
163	Gastrointestinal Infection with <i>Campylobacter jejuni</i> 81â€“176 Produces Altered Bowel Function and Bacterial Overgrowth in Rats. <i>American Journal of Gastroenterology</i> , 2006, 101, S472.	0.4	3
164	The Prevalence of Irritable Bowel Syndrome in Patients With Typical Symptoms Referred to the Gastroenterologist: A Systematic Review. <i>American Journal of Gastroenterology</i> , 2015, 110, S758.	0.4	3
165	T2085 Methane on Breath Testing is Associated With Constipation: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2010, 138, S-629.	1.3	2
166	Tu2030 Quantitation of Bacteria in Duodenal Aspirates by qPCR Appears to Identify Viable Organisms in IBS. <i>Gastroenterology</i> , 2013, 144, S-908.	1.3	2
167	Tu2029 Deep Sequencing Reveals That the Microbiome of the Human Duodenum Is Unique and Unrelated to Stool Bacterial Profiling. <i>Gastroenterology</i> , 2013, 144, S-908.	1.3	2
168	Rifaximin Repeat Treatment in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Produced No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. <i>American Journal of Gastroenterology</i> , 2015, 110, S761.	0.4	2
169	Tu1804 Anti-Vinculin and Anti-CdtB Antibodies in Mexican Subjects: A Case Control Study. <i>Gastroenterology</i> , 2016, 150, S952.	1.3	2
170	Reply. <i>Gastroenterology</i> , 2016, 150, 278-279.	1.3	2
171	Autoimmunity as a Potential Cause of Post-Infectious Gut Dysmotility: A Longitudinal Observation. <i>American Journal of Gastroenterology</i> , 2017, 112, 656-657.	0.4	2
172	Safety and Tolerability of High-Resolution Esophageal Manometry: A Large Database Analysis. <i>Gastroenterology</i> , 2017, 152, S325.	1.3	2
173	Sa1219 - Validation of a 4-Gas Device for Breath Testing in the Determination of Small Intestinal Bacterial Overgrowth. <i>Gastroenterology</i> , 2018, 154, S-281.	1.3	2
174	Ultraviolet-A light reduces cellular cytokine release from human endotracheal cells infected with Coronavirus. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 35, 102457.	2.6	2
175	Intestinal <i>Methanobrevibacter smithii</i> but Not Total Bacteria Is Related to Diet-Induced Weight Gain in Rats. <i>Obesity</i> , 0, , .	3.0	2
176	Rifaximin and Neomycin in the Treatment of Constipation IBS with Methane as a Biomarker on Breath Testing: Presidential Poster. <i>American Journal of Gastroenterology</i> , 2013, 108, S563.	0.4	2
177	The Response of the Rodent Gut Microbiome to Broad-Spectrum Antibiotics Is Different in Males and Females. <i>Frontiers in Microbiology</i> , 0, 13, .	3.5	2
178	Response to Dr. Riordan et al.. <i>American Journal of Gastroenterology</i> , 2001, 96, 2507-2508.	0.4	1
179	Healthy Controls Are Not Appropriately Identified for Comparison to Irritable Bowel Syndrome in Case Control Studies. <i>Gastroenterology</i> , 2011, 140, S-799.	1.3	1
180	Methane-Producing Subjects Have Higher Serum Glucose Levels During Oral Glucose Challenge Than Non-Methane Producers. <i>Gastroenterology</i> , 2011, 140, S-193.	1.3	1

#	ARTICLE	IF	CITATIONS
181	Lymphocytic Esophagitis is Uncommon in Adult Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2011, 140, S-228.	1.3	1
182	Time to Onset and Durability of Relief in Non-Constipation IBS Patients Over 12 Weeks Following a 2-Week Course of Rifaximin. <i>Gastroenterology</i> , 2011, 140, S-605.	1.3	1
183	Daily Variation of Bowel Habits Predicts a Diagnosis of IBS Among Patients Referred to a General Gastroenterologist for Evaluation of Chronic Diarrhea: Validation of the LA/IBS Diagnostic Strategy. <i>Gastroenterology</i> , 2011, 140, S-800.	1.3	1
184	Recorded Lower Esophageal Pressures as a Function of Electronic Sleeve Placement and Location of Gastric Pressure Measurement in Patients With Hiatal Hernia. <i>Journal of Neurogastroenterology and Motility</i> , 2013, 19, 479-484.	2.4	1
185	SYN-010 Modified-Release Lovastatin Does Not Significantly Alter Lipid Parameters at Doses that Reduce Methane and Alleviate Symptoms in Patients Suffering Irritable Bowel Syndrome with Constipation (IBS-C). <i>American Journal of Gastroenterology</i> , 2016, 111, S256-S257.	0.4	1
186	Mo1314 Effect of Rifaximin Treatment on Anti-Vinculin Antibodies in IBS With Diarrhea. <i>Gastroenterology</i> , 2016, 150, S695.	1.3	1
187	Cytotoxic Distending Toxin B (CdtB) Exposure Alone is Sufficient to Precipitate Autoimmunity and Changes to the Small Intestinal Microbiome in a Rat Model of Post-Infectious IBS. <i>Gastroenterology</i> , 2017, 152, S621.	1.3	1
188	Phenotype and Antibiotic Response in Patients With Flat Line Breath Test Results: A Large Scale Database Analysis. <i>American Journal of Gastroenterology</i> , 2018, 113, S261.	0.4	1
189	Sa1912 “Revealing the Entire Intestinal Microbiota and Its Associations to the Genetic, Immunologic, and Neuroendocrine Ecosystems: Methodology for the Reimagine Study. <i>Gastroenterology</i> , 2019, 156, S-450.	1.3	1
190	Su1949 “Small Intestinal Aspirates Require Specific Treatment to Optimize Microbial Analysis: Validation of a Novel Technique from the Reimagine Study. <i>Gastroenterology</i> , 2019, 156, S-670.	1.3	1
191	Declining Rates of Referral for Irritable Bowel Syndrome Without Constipation at a Tertiary Care Center. <i>Digestive Diseases and Sciences</i> , 2019, 64, 182-188.	2.3	1
192	Small Intestinal Bacterial Overgrowth. , 2015, , 125-136.		1
193	Proton Pump Inhibitors Do Not Affect the Lactulose Hydrogen Breath Test in IBS Subjects. <i>American Journal of Gastroenterology</i> , 2009, 104, S495.	0.4	1
194	Pathogen-specific Risk of Functional Gastrointestinal Disorders, Gastroesophageal Reflux Disease and Celiac Disease Following Acute Enteric Infection. <i>American Journal of Gastroenterology</i> , 2011, 106, S512.	0.4	1
195	Rectal Hypersensitivity in Patients with Irritable Bowel Syndrome Compared to Healthy Control: A Systemic Review of Literature. <i>American Journal of Gastroenterology</i> , 2012, 107, S714.	0.4	1
196	Rise in Hydrogen Production During Lactulose Breath Test Does Not Represent Oro-Cecal Transit Due to Lag in Peak Fermentation. <i>American Journal of Gastroenterology</i> , 2012, 107, S716.	0.4	1
197	Anti-vinculin Antibodies: Multicenter Validation of a Diagnostic Blood Test for Irritable Bowel Syndrome: ACG Governors Award for Excellence in Clinical Research. <i>American Journal of Gastroenterology</i> , 2013, 108, S571.	0.4	1
198	Lactulose Breath Testing Predicts the Response to Rifaximin. <i>American Journal of Gastroenterology</i> , 2017, 112, S227.	0.4	1

#	ARTICLE	IF	CITATIONS
199	Unique Differences in Breath Test Gas Patterns in Inflammatory Bowel Disease (IBD) Compared to Non-IBD Patients: A Large-Scale Database Linkage Analysis. American Journal of Gastroenterology, 2018, 113, S381-S382.	0.4	1
200	Significant Overlap between IBS and GERD. American Journal of Gastroenterology, 2005, 100, S324.	0.4	1
201	The Efficacy of the GLP-1 Agonist Exenatide in the Treatment of Short Bowel Syndrome. American Journal of Gastroenterology, 2007, 102, S201-S202.	0.4	1
202	Identification of Rumination with Impedance Manometry and High-Resolution Manometry. American Journal of Gastroenterology, 2008, 103, S29.	0.4	1
203	Increased Risk of IBD Among Military Personnel with IBS. American Journal of Gastroenterology, 2010, 105, S460.	0.4	1
204	The Treatment of Patients With Irritable Bowel Syndrome: Review of the Latest Data From the 2010 DDW Meeting. Gastroenterology and Hepatology, 2010, 6, 1-15.	0.1	1
205	Ultraviolet-A light increases mitochondrial anti-viral signaling protein in confluent human tracheal cells via cell-cell signaling. Journal of Photochemistry and Photobiology B: Biology, 2022, 226, 112357.	3.8	1
206	Response to Drs. Mishkin. American Journal of Gastroenterology, 2001, 96, 2505-2506.	0.4	0
207	A Systematic Review of Diagnostic Testing for Small Intestinal Bacterial Overgrowth. American Journal of Gastroenterology, 2007, 102, S202.	0.4	0
208	Nightly Tegaserod Prevents the Clinical Recurrence of Bacterial Overgrowth Symptoms. American Journal of Gastroenterology, 2007, 102, S499.	0.4	0
209	The Responsiveness and Validity of a Binary Weekly Recall Question and the Proposed FDA Composite Endpoint as Measures of Daily Symptom Severity in Non-Constipation Irritable Bowel Syndrome: Results of TARGET 1 and TARGET 2. American Journal of Gastroenterology, 2010, 105, S494.	0.4	0
210	Rifaximin Treatment Consistently Demonstrated Relief Across Daily Symptoms in Patients with Non-Constipation Irritable Bowel Syndrome: Results from 2 Phase 3 Trials (TARGET 1 and TARGET 2). American Journal of Gastroenterology, 2010, 105, S483-S484.	0.4	0
211	Increased Risk for IGE Among Those with IBS. American Journal of Gastroenterology, 2010, 105, S494.	0.4	0
212	Antibodies to Campylobacter Jejuni Cytolethal Distending Toxin Subunit B (CDT-B) Bind Enteric Neural Elements in Uninfected Mice Suggesting Molecular Mimicry. Gastroenterology, 2011, 140, S-521.	1.3	0
213	Antibodies to an 18-Residue Peptide of Cdt Are Found in the Serum of Rats in a Model of Post-Infectious IBS. Gastroenterology, 2011, 140, S-371.	1.3	0
214	Expression of B-Defensin-2 and Other PRO-Inflammatory Mediators Notable in IBS Are Increased in Rat Mucosa During Acute Campylobacter Jejuni Infection. Gastroenterology, 2011, 140, S-602.	1.3	0
215	Validating a New Genomic Test for Irritable Bowel Syndrome. Gastroenterology, 2011, 140, S-798.	1.3	0
216	Dietary Fat Content Influences the Natural Colonization of Sprague-Dawley Rats With Methanobrevibacter Smithii. Gastroenterology, 2011, 140, S-333.	1.3	0

#	ARTICLE	IF	CITATIONS
217	Repeat Exposure to C. Jejuni Increases the Development of SIBO in a Rat Model of Post-Infectious IBS. Gastroenterology, 2011, 140, S-602-S-603.	1.3	0
218	1134 The Utility of Measuring Anti-Cytolethal Distending Toxin B and Anti-Vinculin Antibodies in a Tertiary Care Motility Practice: A Free Range Experience. Gastroenterology, 2016, 150, S230.	1.3	0
219	257 Assessment of Anti-Vinculin and Anti-CdtB Antibodies in IBS Subtypes. Gastroenterology, 2016, 150, S62.	1.3	0
220	Autoimmunity and Irritable Bowel Syndrome: New Pathophysiology. American Journal of Gastroenterology Supplements (Print), 2016, 3, 41-45.	0.7	0
221	Mo1311 Evaluating the Safety and Efficacy of Eluxadoline for Treating Diarrhea-Predominant Irritable Bowel Syndrome: A Meta-Analysis. Gastroenterology, 2016, 150, S694.	1.3	0
222	Tu1750 Gastrointestinal (GI) Symptoms Associated With Excessive Intestinal Methane Production in the Pediatric Population: A Large Database Analysis. Gastroenterology, 2016, 150, S933-S934.	1.3	0
223	Mo1319 Syn-010, a Proprietary Modified-Release Formulation of Lovastatin Lactone, May Improve Constipation by Inhibiting Enzymes in the Archaeal Methanogenesis Pathway: Results of Computational M. Smithii Enzyme-Ligand Docking Experiments. Gastroenterology, 2016, 150, S696-S697.	1.3	0
224	Su1793 Breath Methane and Hydrogen Composition in Inflammatory Bowel Disease (IBD) Is Strikingly Different From Non-IBD Patients and Is Associated With IBD-Associated Genes: A Large-Scale Database Linkage Analysis. Gastroenterology, 2016, 150, S553.	1.3	0
225	Examination of the effects of breath hydrogen and methane levels on the EC/IR II. Journal of the Canadian Society of Forensic Science, 2017, 50, 125-130.	0.9	0
226	Sustained Response and Predictors of Sustained Response in Patients who Respond to Multiple Courses of Rifaximin for Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology, 2017, 152, S918.	1.3	0
227	Declining Rates of Referral to Tertiary Care Center for IBS-D. Gastroenterology, 2017, 152, S720.	1.3	0
228	Characterization of Abdominal Pain Response in Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Rifaximin. Gastroenterology, 2017, 152, S915.	1.3	0
229	Responders Analysis in Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Treated With Rifaximin. American Journal of Gastroenterology, 2017, 112, S236.	0.4	0
230	Small Intestinal Bacterial Overgrowth. , 2018, , 333-342.		0
231	High-Resolution Manometry Anorectal Manometry. American Journal of Gastroenterology, 2006, 101, S218.	0.4	0
232	Rifaximin Is Superior to Other Antibiotics in Treating and Retreating Bacterial Overgrowth in IBS, Supporting a Lack of Bacterial Resistance Development. American Journal of Gastroenterology, 2006, 101, S475.	0.4	0
233	In the Treatment of IBS, the Clinical Response to Rifaximin Is Determined by the Normalization of the Lactulose Breath Test. American Journal of Gastroenterology, 2006, 101, S474-S475.	0.4	0
234	Methane Production in IBS Subjects Is Associated with a Constellation of Symptoms: Not Just Constipation. American Journal of Gastroenterology, 2007, 102, S499-S500.	0.4	0

#	ARTICLE	IF	CITATIONS
235	Severity of Irritable Bowel Syndrome-Related Symptoms Predicts Clinical Response to the Nonsystemic Antibiotic Rifaximin. American Journal of Gastroenterology, 2008, 103, S463.	0.4	0
236	Evaluating Breath Methane as a Diagnostic Test for Constipation Predominant IBS. American Journal of Gastroenterology, 2008, 103, S458.	0.4	0
237	A Combination of Rifaximin and Neomycin Is Most Effective in Treating Patients with Methane on Lactulose Breath Test. American Journal of Gastroenterology, 2008, 103, S465-S466.	0.4	0
238	Validation of a Simple Tool (Constipation Minus Diarrhea) for Evaluating Constipation Symptom Outcomes in IBS. American Journal of Gastroenterology, 2009, 104, S495-S496.	0.4	0
239	Incontinence and Anal Sphincter Pressure Predicts Rectal Sensitivity During High Resolution Anorectal Manometry. American Journal of Gastroenterology, 2009, 104, S485.	0.4	0
240	New Onset Gastroesophageal Reflux Disease After Acute Gastroenteritis: A Case of Post-Infectious GERD?. American Journal of Gastroenterology, 2009, 104, S367.	0.4	0
241	The Methanobrevibacter smithii Concentration in Stool of Subjects with Constipation Predominant IBS is Directly Correlated with Methane on Lactulose Breath Test. American Journal of Gastroenterology, 2010, 105, S500.	0.4	0
242	Defining Normal Bowel Function Relative to GI Disease: A Systematic Review of the Literature. American Journal of Gastroenterology, 2010, 105, S501.	0.4	0
243	Understanding Harm in the Pharmacotherapy of Irritable Bowel Syndrome with Diarrhea. American Journal of Gastroenterology, 2011, 106, S496.	0.4	0
244	Evaluation of Rifaximin Efficacy in Non C-IBS Patients by Baseline Disease Severity: Subanalysis of the TARGET 1 and TARGET 2 Studies. American Journal of Gastroenterology, 2011, 106, S505-S506.	0.4	0
245	Gender of Gastroenterologist and Years in Practice are Important in Drug Selection for D-IBS. American Journal of Gastroenterology, 2012, 107, S715.	0.4	0
246	Responsiveness of a Tri-Component Endpoint in Non-Constipation Irritable Bowel Syndrome: Pooled Results from Two Phase 3 Trials, TARGET 1 and TARGET 2. American Journal of Gastroenterology, 2012, 107, S712.	0.4	0
247	The Effect of Rifaximin on Staphylococcus Species in the Stool. American Journal of Gastroenterology, 2012, 107, S228.	0.4	0
248	Diagnosis of Pellagra Should Be Considered in Patients Suspicious for Crohn's. American Journal of Gastroenterology, 2012, 107, S379.	0.4	0
249	The Effect of Dried Plum on Targeted Gut Flora and Host Gene Expression in a Rat Model of Post-infectious IBS. American Journal of Gastroenterology, 2014, 109, S537.	0.4	0
250	â€œStack of Coinsâ€ on Manometry: Type 3 Achalasia Complicated by Severe Esophageal Diverticulosis. American Journal of Gastroenterology, 2015, 110, S269-S270.	0.4	0
251	Antibiotic Susceptibility of Skin Swab Staphylococcus Isolates From Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Treated With Repeat Courses of Rifaximin Showed No Evidence of Resistance. American Journal of Gastroenterology, 2015, 110, S751.	0.4	0
252	Improvements over Time in Individual Diarrhea-Predominant Irritable Bowel Syndrome Symptoms (IBS-D) with Rifaximin Repeat Treatment. American Journal of Gastroenterology, 2016, 111, S240.	0.4	0

#	ARTICLE	IF	CITATIONS
253	Safety and Tolerability of Rifaximin in the Treatment of Irritable Bowel Syndrome (IBS): A Pooled Analysis of 4 Randomized, Placebo-Controlled Trials. American Journal of Gastroenterology, 2016, 111, S253.	0.4	0
254	Development and Seroconversion of Anti-Cytolethal Distending Toxin(CdtB) and Anti-Vinculin Antibodies in a Patient with Evolving Post-infectious IBS. American Journal of Gastroenterology, 2016, 111, S807.	0.4	0
255	Efficacy of Rifaximin on Bowel Movement Urgency in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D): A Pooled Analysis of 3 Phase 3 Trials. American Journal of Gastroenterology, 2016, 111, S253-S254.	0.4	0
256	Does Bacterial Overgrowth Affect Breath Alcohol Levels on DUI Testing?: 2016 ACG Presidential Poster Award. American Journal of Gastroenterology, 2016, 111, S467.	0.4	0
257	Assessing the Efficacy of Rifaximin in Diarrhea-Predominant Irritable Syndrome (IBS-D): A Post hoc Analysis of 2 Phase 3, Randomized, Placebo-Controlled Trials. American Journal of Gastroenterology, 2017, 112, S254.	0.4	0
258	Lactulose Breath Testing Predicts Response to Rifaximin for Cardinal Irritable Bowel Syndrome With Diarrhea (IBS-D). American Journal of Gastroenterology, 2018, 113, S270.	0.4	0
259	Irritable bowel syndrome: Bacterial overgrowth—What's known and what to do. Current Treatment Options in Cardiovascular Medicine, 2007, 10, 328-337.	0.9	0
260	Case studies of antibiotic therapy in the management of functional gastrointestinal disorders. Gastroenterology and Hepatology, 2007, 3, 1-12.	0.1	0
261	Update on Irritable Bowel Syndrome Diagnostics and Therapeutics. Gastroenterology and Hepatology, 2016, 12, 442-5.	0.1	0